Life Sciences

Life sciences encompasses pharmaceutical, biotech, medical device, and healthcare organizations that develop treatments and conduct clinical research. These sectors face unique AI governance challenges around regulatory compliance with FDA and EMA requirements, clinical validation of AI-driven diagnostics, and data privacy obligations under HIPAA and similar regulations. Effective AI governance in life sciences must balance innovation speed with rigorous oversight of AI systems used in drug discovery, patient monitoring, and medical imaging.

1 item

ResearchGlobal2026-08-15

AI-Designed Viruses Expose a Dual-Use Gap in Enterprise Governance Programs

Stanford researchers used the Evo 2 genomic language model to generate 16 functional bacteriophage genomes from scratch, with findings published in Science on August 6, 2026. Biosecurity experts at the Johns Hopkins Center for Health Security warn that the same methods lower the technical barrier to designing harmful biological agents. The research has prompted explicit calls for societal oversight frameworks, raising compliance obligations for any enterprise deploying or procuring AI tools with biological design capabilities.

biosecurity dual-use AI AI safety generative biology CBRN Stanford University Johns Hopkins life sciences